DE60120131T2 - Antiangiogene Eigenschaften von Vascostatin und Fragmenten und Varianten davon - Google Patents

Antiangiogene Eigenschaften von Vascostatin und Fragmenten und Varianten davon Download PDF

Info

Publication number
DE60120131T2
DE60120131T2 DE60120131T DE60120131T DE60120131T2 DE 60120131 T2 DE60120131 T2 DE 60120131T2 DE 60120131 T DE60120131 T DE 60120131T DE 60120131 T DE60120131 T DE 60120131T DE 60120131 T2 DE60120131 T2 DE 60120131T2
Authority
DE
Germany
Prior art keywords
protein
polynucleotide
fragments
fragment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60120131T
Other languages
German (de)
English (en)
Other versions
DE60120131D1 (de
Inventor
Raghuram Boston KALLURI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center
Original Assignee
Beth Israel Deaconess Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center filed Critical Beth Israel Deaconess Medical Center
Application granted granted Critical
Publication of DE60120131D1 publication Critical patent/DE60120131D1/de
Publication of DE60120131T2 publication Critical patent/DE60120131T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
DE60120131T 2000-03-29 2001-03-28 Antiangiogene Eigenschaften von Vascostatin und Fragmenten und Varianten davon Expired - Fee Related DE60120131T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19287100P 2000-03-29 2000-03-29
US192871P 2000-03-29
PCT/US2001/040382 WO2001073025A2 (en) 2000-03-29 2001-03-28 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains

Publications (2)

Publication Number Publication Date
DE60120131D1 DE60120131D1 (de) 2006-07-06
DE60120131T2 true DE60120131T2 (de) 2007-01-04

Family

ID=22711364

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120131T Expired - Fee Related DE60120131T2 (de) 2000-03-29 2001-03-28 Antiangiogene Eigenschaften von Vascostatin und Fragmenten und Varianten davon

Country Status (8)

Country Link
EP (1) EP1268798B1 (enExample)
JP (1) JP2003528609A (enExample)
AT (1) ATE328081T1 (enExample)
AU (1) AU8727401A (enExample)
CA (1) CA2403515A1 (enExample)
DE (1) DE60120131T2 (enExample)
NZ (1) NZ521567A (enExample)
WO (1) WO2001073025A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525595A (ja) * 1999-11-01 2003-09-02 キュラゲン コーポレイション 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
CN1455682A (zh) 2001-01-05 2003-11-12 百疗医株式会社 包括编码抗－血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
EP3842452A1 (en) 2019-12-26 2021-06-30 Universitat Autònoma de Barcelona Scaffold proteins and therapeutic nanoconjugates based on nidogen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides

Also Published As

Publication number Publication date
CA2403515A1 (en) 2001-10-04
WO2001073025A2 (en) 2001-10-04
WO2001073025A3 (en) 2002-06-27
ATE328081T1 (de) 2006-06-15
NZ521567A (en) 2004-04-30
EP1268798B1 (en) 2006-05-31
DE60120131D1 (de) 2006-07-06
JP2003528609A (ja) 2003-09-30
AU8727401A (en) 2001-10-08
EP1268798A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DE60217507T2 (de) Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
DE69838061T2 (de) Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
DE69534402T2 (de) Apoptose-proteasen 3 und 4, ähnlich dem umwandlungsenzym für interleukin-1beta
JP2020186256A (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
HUP0004611A2 (hu) APRIL, egy új növekedési hatású fehérje
JPH05503003A (ja) 潜在性関与ペプチドおよびその使用
JP2009278975A (ja) 線維芽細胞増殖因子レセプター様分子およびその使用
CN109248310B (zh) 利用θ-防御素的炎性蛋白酶的阻断
DE60019147T2 (de) Fibrinolytisch wirksames polypeptid
KR20010015869A (ko) 레스틴 및 그의 사용 방법
JP2002517999A (ja) 抗血管形成タンパク質およびその使用方法
CA2509400A1 (en) Nk cell receptor conjugates for treating malignancies
DE60121146T2 (de) Anti-angiogenic properties of matin and of fragments or variants thereof
EP1165111A1 (en) Method for pr-39 peptide regulated stimulation of angiogenesis
TWI238191B (en) IL-17 like molecules and uses thereof
EP3884055B1 (en) Double and inducible suicide gene construct and its use in gene therapy
EP1268798B1 (en) Anti-angiogenic properties of vascostatin and fragments or variants thereof
JP7774268B2 (ja) 組換え霊芝免疫調節タンパク質の新規変異体及びその応用
DE60030850T2 (de) Verfahren zur behandlung von tumoren mittels antiangiogener substanzen
WO2001030368A1 (en) Method for pr-39 peptide regulated stimulation of angiogenesis
US7700134B2 (en) Prevention of cisplatin induced deafness
US20080167232A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other indogen domains
DE60024450T2 (de) Modulierung der angiogenese durch verwendung von anti-angiogenischen angiotensin-7 und dafür kodierende polynukleotiden zur behandlung von tumoren
WO2005023312A2 (en) Methods for transfecting cells using dna minor groove binding agents
CA2480419A1 (en) Antiopoietin-related growth factor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee